Ran Tao, Kristine Ruppert, Ruy J. Cruz, Shahid M. Malik, Obaid Shaikh, Jawad Ahmad, Andrea DiMartini, Abhinav Humar, Paulo A. Fontes, Michael E. de Vera – 27 August 2010 – Many factors can worsen a recurrent hepatitis C virus (HCV) infection after liver transplantation (LT). We sought to determine whether the use of donation after cardiac death (DCD) livers affects HCV recurrence. From January 2000 to June 2008, 37 HCV patients underwent LT with DCD allografts.

Tarun K. Narang, Will Ahrens, Mark W. Russo – 27 August 2010 – Liver transplantation is currently the only definitive modality for the treatment of end‐stage liver disease due to chronic hepatitis C. However, recurrent hepatitis C after liver transplantation is nearly universal. Cirrhosis may develop in 20% of recipients within 5 years, and recurrent hepatitis C may lead to graft failure, retransplantation, and even death.

André A. S. Dick, James D. Perkins, Austin L. Spitzer, Oliver B. Lao, Patrick J. Healey, Jorge D. Reyes – 27 August 2010 – Controversies exist with respect to the mortality of patients undergoing liver transplantation at the extremes of the body mass index (BMI). For pediatric liver transplantation, weight is usually the only factor considered in survival analysis. A review of the United Network for Organ Sharing database (1987‐2007) revealed 9701 pediatric patients (<18 years old) who underwent primary liver transplantation.

Laura Lladó, Carme Baliellas, Carlos Casasnovas, Isidre Ferrer, Joan Fabregat, Emilio Ramos, Jose Castellote, Jaume Torras, Xavier Xiol, Antoni Rafecas – 27 August 2010 – Recent reports of the transmission of systemic transthyretin (TTR) amyloidosis after domino liver transplantation (DLT) using grafts from patients with familial amyloid polyneuropathy (FAP) have raised concerns about the procedure. The aim of this study was to evaluate the transmission incidence of systemic TTR amyloidosis after DLT with a complete clinical, neurological, and pathological assessment.

Taku Iida, Toshimi Kaido, Shintaro Yagi, Atsushi Yoshizawa, Koichiro Hata, Masaki Mizumoto, Akira Mori, Yasuhiro Ogura, Fumitaka Oike, Shinji Uemoto – 27 August 2010 – Infectious complications such as bacteremia after living donor liver transplantation (LDLT) are associated with significant morbidity and mortality. We retrospectively analyzed the frequency and characteristics of posttransplant bacteremia in 181 adult LDLT recipients between April 2006 and November 2009, and we evaluated the risk factors for posttransplant bacteremia.

Harendra Arora, Janine Thekkekandam, Leora Tesche, Raeshell Sweeting, David A. Gerber, Paul H. Hayashi, Kenneth Andreoni, Tomasz Kozlowski – 27 August 2010 – Primary liver allograft nonfunction immediately after transplantation poses a life‐threatening situation for the recipient. Emergency retransplantation may not be immediately possible due to organ unavailability. Total hepatectomy with temporary portacaval shunt has been described as a bridge to retransplantation when the presence of the graft appears to be harming the recipient.

Otmane Nafidi, Denis Marleau, André Roy, Marc Bilodeau – 27 August 2010 – We currently face the more widespread use of marginal livers for organ transplantation. Therefore, it is imperative to adequately identify the factors affecting early and late graft survival in that setting. The objective of this study was to determine the donor variables associated with graft survival in the liver transplant program of the University of Montreal. We retrospectively studied the survival of 634 grafts transplanted into 634 recipients between 1990 and 2008.

Cindy Ka Yee Cheung, Chung Mau Lo, Kwan Man, George Ka Kit Lau – 27 August 2010 – Liver grafts from donors positive for antibody to hepatitis B core antigen (anti‐HBc) may be used for transplantation in patients with hepatitis B virus (HBV)–related liver disease, and an occult HBV infection may develop from either source. Liver biopsy was performed for 31 patients who remained seronegative for hepatitis B surface antigen for a median of 44.5 months (range = 13.6‐126.4 months) and received nucleoside analogue prophylaxis post‐transplant.

Christopher L. Bowlus, Chin‐Shang Li, Tom H. Karlsen, Benedicte A. Lie, Carlo Selmi – 27 August 2010 – Primary sclerosing cholangitis (PSC) is well characterized in European populations. We aimed to characterize clinical characteristics and human leukocyte antigen (HLA) associations in a population of European American, Hispanic, and African American PSC patients listed for liver transplantation (LT).

Federico Salamone, Fabio Galvano, Giovanni Li Volti – 26 August 2010